全文获取类型
收费全文 | 1177篇 |
免费 | 35篇 |
国内免费 | 8篇 |
专业分类
耳鼻咽喉 | 15篇 |
儿科学 | 11篇 |
妇产科学 | 53篇 |
基础医学 | 68篇 |
口腔科学 | 21篇 |
临床医学 | 97篇 |
内科学 | 347篇 |
皮肤病学 | 6篇 |
神经病学 | 76篇 |
特种医学 | 49篇 |
外科学 | 232篇 |
综合类 | 6篇 |
预防医学 | 36篇 |
眼科学 | 59篇 |
药学 | 87篇 |
肿瘤学 | 57篇 |
出版年
2023年 | 4篇 |
2022年 | 13篇 |
2021年 | 32篇 |
2020年 | 24篇 |
2019年 | 42篇 |
2018年 | 38篇 |
2017年 | 32篇 |
2016年 | 32篇 |
2015年 | 24篇 |
2014年 | 37篇 |
2013年 | 59篇 |
2012年 | 80篇 |
2011年 | 84篇 |
2010年 | 53篇 |
2009年 | 66篇 |
2008年 | 105篇 |
2007年 | 102篇 |
2006年 | 92篇 |
2005年 | 78篇 |
2004年 | 59篇 |
2003年 | 42篇 |
2002年 | 58篇 |
2001年 | 6篇 |
2000年 | 9篇 |
1999年 | 5篇 |
1998年 | 4篇 |
1997年 | 8篇 |
1996年 | 5篇 |
1995年 | 9篇 |
1994年 | 1篇 |
1992年 | 2篇 |
1991年 | 4篇 |
1990年 | 1篇 |
1989年 | 1篇 |
1983年 | 3篇 |
1982年 | 1篇 |
1981年 | 1篇 |
1979年 | 3篇 |
1969年 | 1篇 |
排序方式: 共有1220条查询结果,搜索用时 15 毫秒
1.
2.
3.
Mitzi S. Laughlin Emily A. Vidal Arin A. Drtil Robin N. Goytia Vasilios Mathews Anay R. Patel 《The Journal of arthroplasty》2021,36(7):2353-2358
BackgroundIn counseling patients about the complications of revision total hip arthroplasty (revTHA), it is imperative that mortality be considered. The actual mortality rate by indication of revision is ill-defined. The purpose of this study is to determine the mortality rate after revTHA.MethodsAn institutional database identified 596 patients who had undergone revTHA between 2012 and 2018. Medical records, national, state, and local death indexes were queried for mortality status and indication for revTHA. For survivors, the last clinical visit date was used for censoring in the mortality analysis. Mortality rates were calculated for all clinical patients and then by specific indication for revision.ResultsThe overall 2-year mortality rate following revTHA was 19.5 deaths per 1000 or 1 in 51 patients. Patients presenting with a periprosthetic fracture had a significantly higher 2-year mortality rate of 74.5 deaths per 1000 or 1 in 13 patients (P < .001), while an indication of dislocation or instability had a slightly higher 2-year mortality rate of 50.3 per 1000 (1 in 20) but this difference was not significant (P = .531). Other indications such as mechanical loosening or infection did not have a significantly different mortality rate.ConclusionThe overall 2-year mortality rate following revTHA was 19.5 deaths per 1000 which was largely attributed to patients with a periprosthetic fracture (74.5 per 1000) with other indications not significantly impacting mortality. Mortality rates and specific rates by indication for revision should be considered when counseling patients prior to revTHA. 相似文献
4.
Vasilios Tanos Shevach Friedler Asher Shushan Nurith Strauss Iftach Hetsroni Aby Lewin 《Journal of assisted reproduction and genetics》1995,12(10):715-719
Purpose
Nafarelin acetate is a new gonadotropin releasing (GnRH) agonist analogue with unique potency, intranasal administration, and convenient storage. Hence, nafarelin was considered as an alternative for temporary pituitary suppression in patients undergoing ovulation induction in IVF. A crossover treatment in a prospective study was performed including 40 women with bilateral obstructed tubes and normal ovarian function, treated in 80 ovulation induction cycles using the long protocol. Twenty patients used nafarelin acetate 600 g/daily in their first cycle and received
d-Trp6-LHRH, 0.5 mg/daily, in their following cycle. The other 20 women used decapeptyl in their first cycle and received nafarelin in the second.Results
Estradiol suppression was achieved by both
d-Trp6-LHRH and nafarelin at equal time intervals. The average total number of ampoules (P=0.0005) and the length of administration of hMG required for ovarian stimulation (P=0.0002) and the time interval between GnRHa initiation to oocyte retrieval (P=0.04) was significantly lower in nafarelin cycles. The number and the distribution between large and small follicles as well as the average number of oocytes retrieved did not differ between the two GnRH analogues.Conclusion
Our results demonstrate that nafarelin acetate is comparable to
d-Trp6-LHRH for temporary pituitary suppression used for controlled ovarian stimulation in IVF patients. However, using nafarelin ovarian stimulation was achieved with fewer ampoules of hMG, administered for a shorter period of time, thus with a lesser cost. 相似文献
5.
6.
Patients with first-episode psychosis (FEP) often adopt unhealthy dietary patterns, with a risk of weight gain and metabolic and cardiovascular disease. In 21 FEP patients receiving nutritional intervention based on the Mediterranean diet (MedDiet), we explored differences in anthropometric and biometric parameters, according to their antipsychotic (AP) medication: AP1, associated with a lower risk, or AP2, associated with a higher risk of weight gain and metabolic complications. The blood biochemical profile was recorded before and after dietary intervention, and dietary habits and body composition were monitored for six months. Following intervention, all of the patients recorded significant increases in the consumption of fruit and vegetables and decreases in red meat and poultry consumption, with closer adherence to the MedDiet and a reduction in the daily intake of calories, carbohydrates, and sodium. Vegetable consumption and energy, protein, and carbohydrate intake were lower in AP1 patients than in AP2 patients. There was no significant weight gain overall. A reduction was demonstrated in total and LDL cholesterol, sodium, urea, and iron (lower in AP1 patients). It was evident that AP medication affected blood levels of lipids, urea, and iron of FEP patients, but MedDiet nutritional intervention led to a significant improvement in their eating habits, with a restriction in weight gain and a decrease in blood sodium and urea. 相似文献
7.
8.
Papademetriou V 《The American journal of cardiology》2003,91(4):433-435
9.
10.
Chinali M de Simone G Wachtell K Gerdts E Gardin JM Boman K Nieminen MS Papademetriou V Dahlöf B Devereux RB 《Journal of hypertension》2008,26(7):1472-1476
In hypertensive patients without prevalent cardiovascular disease, enhanced left atrial systolic force is associated with left ventricular hypertrophy and increased preload. It also predicts cardiovascular events in a population with high prevalence of obesity. Relations between left atrial systolic force and left ventricular geometry and function have not been investigated in high-risk hypertrophic hypertensive patients. Participants in the Losartan Intervention For Endpoint reduction in hypertension echocardiography substudy without prevalent cardiovascular disease or atrial fibrillation (n = 567) underwent standard Doppler echocardiography. Left atrial systolic force was obtained from the mitral orifice area and Doppler mitral peak A velocity. Patients were divided into groups with normal or increased left atrial systolic force (>14.33 kdyn). Left atrial systolic force was high in 297 patients (52.3%), who were older and had higher body mass index and heart rate (all P < 0.01) but similar systolic and diastolic blood pressure, in comparison with patients with normal left atrial systolic force. After controlling for confounders, increased left atrial systolic force was associated with larger left ventricular diameter and higher left ventricular mass index (both P < 0.01). Prevalence of left ventricular hypertrophy was greater (84 vs. 64%; P < 0.001). Participants with increased left atrial systolic force exhibited normal ejection fraction; higher stroke volume, cardiac output, transmitral peak E velocities and peak A velocities; and lower E/A ratio (all P < 0.01). Enhanced left atrial systolic force identifies hypertensive patients with greater left ventricular mass and prevalence of left ventricular hypertrophy, but normal left ventricular chamber systolic function with increased transmitral flow gradient occurring during early filling, consistent with increased preload. 相似文献